Table 2.
Immune-related adverse events and immunosuppression.
| Baseline characteristics | Patients, n = 22 (%) |
|---|---|
| irAE | |
| Grade 1 | 3 (13.6) |
| Grade 2 | 5 (22.7) |
| None | 14 (63.6) |
| Liver irAE | |
| Grade 1 | 2 (9.1) |
| Grade 2 | 1 (4.5) |
| Non–Liver irAE | |
| Colitis | 1 (4.5) |
| Pneumonitis | 1 (4.5) |
| Inflammatory arthritis | 1 (4.5) |
| Rash | 2 (9.1) |
| Treatment regimen before ICI# | |
| Mycophenolate mofetil | 1 (4.5) |
| Azathioprine | 4 (18.1) |
| Corticosteroids | 2 (9.1) |
| Methotrexate* | 1 (4.5) |
| UDCA | 9 (40.9) |
| Obeticholic acid | 1 (4.5) |
| No treatment for AILD | 7 (31.8) |
| Treatment adjustment during ICI therapy due to non-liver related events# | |
| Start Hydroxycholoroquine* | 1 (4.5) |
| Start or increase of corticosteroids | 2 (9.1) |
| No change in treatment | 16 (72.7) |
| Treatment adjustment during ICI therapy due to ILICI or AILD# | |
| Start or increase of corticosteroids | 2 (9.1) |
| Start UDCA | 1 (4.5) |
| Change from obeticholic acid to Fenofibrate | 1 (4.5) |
| Stop Azathioprine | 1 (4.5) |
| No change in treatment | 16 (72.7) |
| Monoclonal antibody used | |
| Atezolizumab | 7 (31.8) |
| Durvalumab | 5 (22.7) |
| Pembrolizumab | 4 (18.1) |
| Nivolumab | 4 (18.1) |
| Nivolumab + Ipilimumab | 1 (4.5) |
| Spartalizumab | 1 (4.5) |
No changes in immunosuppressive therapy were made before commencing ICI treatment to prevent potential irAEs. #Multiple treatments possible *Treatment for Rheumatoid arthritis.